Amgen 2004 Annual Report Download - page 22

Download and view the complete annual report

Please find page 22 of the 2004 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 38

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38

1992
Kevin W.
Sharer
named
president
and chief
operating
offi cer
1993
Regulators in
Australia, Canada
and Europe
approve
NEUPOGEN®
for the treatment
of severe chronic
neutropenia
Amgen receives
Australian,
Canadian,
European
Community and
U.S. regulatory
approval for its
multi-product
manufacturing
facility in
Thousand Oaks
1995
FDA approves
NEUPOGEN®
for use in
peripheral
blood
progenitor
cell (PBPC)
transplants
1998
FDA approves
NEUPOGEN®
for use in
support of
treatment
of acute
myeloid
leukemia
FDA approves
Immunex’s
ENBREL®
to treat
patients with
moderately
to severely
active
rheumatoid
arthritis
1996
Regulators in
Australia
and Canada
approve
NEUPOGEN®
for use
in PBPC
transplants
1994
FDA approves
NEUPOGEN®
for patients
undergoing bone
marrow trans-
plantation and
for patients with
severe chronic
neutropenia
Amgen opens
subsidiary in
Japan, Amgen K.K.
Amgen receives
U.S. Department
of Commerce
National Medal
of Technology,
the nation’s highest
honor for
innovation
Amgen acquires
Synergen, Inc.,
a biotechnology
company based
in Boulder, Colorado
1997
FDA approves
INFERGEN®
for treating
patients with
Hepatitis C
(Today,
INFERGEN®
is marketed
by Yamanouchi
Pharmaceutical
Co., Ltd. in
Japan and by
InterMune, Inc.
in the U.S.)
Amgen 2004 Annual Report page 20